Datapoint: FDA Approves First Soliris Biosimilar

The FDA on May 28 approved Amgen’s Bkemv (eculizumab-aeeb), the first biosimilar to AstraZeneca’s monoclonal antibody Soliris (eculizumab). Bkemv will be an interchangeable biosimilar, approved to treat two rare blood disorders: paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris was first approved in 2007 for the treatment of PNH, an indication for which it currently holds covered or better status for 86% of all insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 6/5/24

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 12

Datapoint: Centene to Expand Cityblock Partnership to Florida

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 11

Datapoint: SCAN Wins Stars Challenge Against CMS

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 10

Datapoint: Blue Cross and Blue Shield of Kansas City to Exit MA Market

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today